Preparing for success in modernizing the science behind the development and regulation of medical products
ACDRS 2024 Session 4 - Statistics: Design, Analysis, and Interpretation of Clinical Trials
Date:
Tuesday, May 14, 2024 - 8:00 am to Thursday, May 16, 2024 - 4:00 pm
Location:
University of California Washington Center (UCDC), 1st floor meeting room
1608 Rhode Island Ave NW, Washington, DC
This is Session 4 of 6. Must register for the entire 2024 Course and not per session.
Session Co-chairpersons:
Telba Irony, PhD, Senior Scientific Director, The Janssen Pharmaceutical Companies of Johnson & Johnson
John Scott, PhD, Director, Division of Biostatistics, Center for Biologics and Evaluation Research, US Food and Drug Administration (FDA)
Topics
- Role of confirmatory phase in drug development
- Statistical principles for clinical trials
- Choice of control groups in clinical trials
- Study objectives, hypothesis testing, sample size, and probability of study success
- Multiplicity in clinical trials
- Missing data and estimands
- Interim analysis
- Bayesian statistics
- The design, analysis, and interpretation of a clinical endpoint trial
- Modeling and simulation
- Adaptive design in clinical trials and optimization
- Design and analysis of adaptive clinical trials
- Enrichment designs
- Perspectives for developing a targeted medicine
- Co-development of a diagnostic and targeted medicine
- Statistical issues related to design, analysis, and reporting of gene therapy clinical trials
- Multi-regional clinical trials
- Safety assessment and surveillance